RJA
MDNA

Raymond James & Associates’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Raymond James & Associates’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,400
Closed -$3.17K – 4093
2023
Q4 		$3.17K Hold
10,400
– – ﹤0.01% 3817
2023
Q3 		$3.07K Hold
10,400
– – ﹤0.01% 3781
2023
Q2 		$5.01K Hold
10,400
– – ﹤0.01% 3822
2023
Q1 		$6.55K Buy
+10,400
New +$6.48K ﹤0.01% 3854

Raymond James & Associates's MDNA Position: Q1 2024 in Review

Raymond James & Associates sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q1 2024, closing a stake of 10,400 shares — an estimated $3.17K sold.

Raymond James & Associates first reported a position in MDNA in Q1 2023 and held it in 4 quarters. The position peaked at $6.55K in Q1 2023. 0 funds tracked by Wall St. Rank hold MDNA as of Q1 2024.

  • Raymond James & Associates reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 10,400 Medicenna Therapeutics Corp. Common Shares shares in Q1 2024, an estimated $3.17K.
  • Raymond James & Associates first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2023 and held it in 4 quarters.
  • Raymond James & Associates's Medicenna Therapeutics Corp. Common Shares position peaked at $6.55K in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.